Pages

▼
Thursday, July 29, 2010

Marina Biotech Continues to Drive Sector Consolidation, Acquires Novosom’s Liposomal Delivery IP

›
Marina Biotech, formerly known as mdRNA, continues to snap up assets in the oligonucleotide therapeutics and diagnostics space, this time a...
9 comments:
Monday, July 26, 2010

Brewing Genzyme Takeover Battle Highlights Value of High-Impact Drug Innovation

›
Orphan disease drug developer Genzyme had emerged as the drug development of the future by developing innovative drugs which have a high imp...
4 comments:
Thursday, July 22, 2010

RXi Reports on Dicer-insensitive 25bp RNAi Triggers

›
There is little question that Alnylam enjoys considerable control over arguably the most desirable type of synthetic RNAi triggers: 19-21 ba...
3 comments:
Friday, July 16, 2010

Tekmira Awarded Ebola Contract, Continues to Build on Momentum

›
The mystery surrounding the abrupt halt to the trading of Tekmira shares on July 14 was solved when Tekmira announced that it was awarded a...
2 comments:
Thursday, July 15, 2010

Tekmira Trading Halt: Time for Some Wild Speculations

›
As many of you will be aware by now, trading of Tekmira shares has been abruptly halted just 15 minutes before market close on Wednesday J...
6 comments:
Wednesday, July 14, 2010

AstraZeneca Shows Continued Commitment Towards RNAi Therapeutics through Partnership with Silence Therapeutics

›
One week after announcing the grant of a US patent covering RNAi triggers with enhanced guide strand loading , Silence Therapeutics today a...
3 comments:
Thursday, July 8, 2010

Silence Therapeutics Issued Important Zamore siRNA Design Rule Patent

›
Silence Therapeutics announced yesterday the issuance of a United States patent related to the design of gene silencing siRNAs. This is th...
8 comments: